



Press release - February 7, 2019

DMS Group and Hybrigenics enter into exclusive negotiation

Diagnostic Medical Systems Group (Euronext Paris - FR0012202497 - DGM) and Hybrigenics (Euronext Growth - FR0004153930 - ALHYG) today announces entering into exclusive negotiation for a takeover of Hybrigenics by DMS Group through the transfer of its DMS Biotech division dedicated to biotechnology.

DMS Biotech is in charge of the development strategy of DMS Group in the field of biotechnology, and especially research based on the injection of adipose stem cells for the treatment of arthrosis and in regenerative medicine. DMS Biotech is composed of the Stemcis company (fully-owned by DMS Group) and of its Adip'Sculpt subsidiary, which sells devices and equipment for lipofilling, an adipose tissue autografting technique used in plastic and reconstructive surgery.

The necessary due diligences, checks and appropriate analyses will start to determine the best conditions in which this operation could be structured to be proposed for potential approval to the shareholders.

At this stage, subject to the outcome of the due diligences and on the basis of a provisional exchange ratio which will need to be confirmed by a "Commissaire aux apports", the parity provisionally set by the parties would be 82% DMS Biotech and 18% Hybrigenics. The conclusion of this operation would therefore be conditioned by the exemption to the obligation to file a public offer, to be granted by the "Autorité des marchés financiers".

The final detailed conditions of the proposed operation will be published at a later date in a subsequent press release.

About DMS Group

DMS Group is composed of companies with a high innovation potential. First focused on medical imaging industry, it now grows to new horizons. Investing in the future and in research, DMS Group aims to bring tomorrow's solutions.

- Specialized in high-technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of medical imaging dedicated to radiology, bone densitometry, 3D modelling and posturology.
- DMS Wellness gathers the activities dedicated to health and wellness, aimed at specialists of physiotherapy, beauty, esthetics and sport.
- **DMS Biotech** accompanies the development strategy of the group in the area of biotechnologies, and more specifically technologies for the treatment of arthritis and regenerative medicine based on the injection of adipose stem cells.

DMS Group is present on every continent through a network of over 140 national distributors, branches and joint-ventures. In 2017, DMS Group reached a consolidated turnover of 27,1 M€. DMS Group is listed on Euronext Paris Exchange (ISIN: FR0012202497 - mnémo: DGM).

More information on www.dms.com.

Contacts

DMS Group

Jean-Paul ANSEL CEO +33 (0)4 67 50 49 00

ACTUS FINANCE

 Mathieu OMNES
 Investors Relations
 +33 (0)1 53 67 36 92

 Alexandra PRISA
 Press Relations
 +33 (0)1 53 67 36 90

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on the Euronext Growth market of Euronext Paris - ISIN: FR0004153930 - Mnemo: ALHYG.

Inecalcitol is a vitamin D receptor agonist active by oral administration. Oral inecalcitol had shown excellent tolerance and presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere[®]. Inecalcitol had also been tested in two pilot clinical Phase II studies in chronic myeloid leukemia and chronic lymphocytic leukemia. Inecalcitol has failed to prolong overall survival of elderly acute myeloid leukemia patients in an international double-blind placebo-controlled Phase II clinical study.

Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.

Hybrigenics Rémi Delansorne Directeur Général Tél.: +33 (0)1 58 10 38 00 investors@hybrigenics.com NewCap Communication financière Pierre Laurent / Mathilde Bohin Tél.: +33 (0)1 44 71 94 94 hybrigenics@newcap.eu